Results 141 to 150 of about 22,911 (183)

Potency of Meropenem-Vaborbactam in Lung Surfactant. [PDF]

open access: yesAntimicrobial Agents and Chemotherapy, 2018
ABSTRACT This study investigated whether pulmonary surfactant has an effect on the in vitro antibacterial activity of either meropenem alone or meropenem in combination with vaborbactam at a fixed concentration of 8 μg/ml against several Klebsiella pneumoniae carbapenemase (KPC ...
Olga Lomovskaya   +2 more
exaly   +4 more sources

Meropenem-Vaborbactam in the Treatment of Acute Bacterial Infections [PDF]

open access: yesJournal of Clinical Medicine, 2019
This study reports the integrated analysis of two phase III studies of meropenem-vaborbactam in the treatment of acute bacterial infections. Targeting Antibiotic Non-Susceptible Gram-Negative Organisms (TANGO) I compared the clinical efficacy and tolerability of meropenem-vaborbactam and piperacillin-tazobactam in the treatment of complicated urinary ...
Chi-Chung Chen   +2 more
exaly   +5 more sources

Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae.

open access: yesAntimicrobial Agents and Chemotherapy, 2018
Meropenem-vaborbactam (Vabomere) is highly active against Gram-negative pathogens, especially Klebsiella pneumoniae carbapenemase (KPC)-producing, carbapenem-resistant Enterobacteriaceae .
Olga Lomovskaya   +2 more
exaly   +2 more sources

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination Following Single and Multiple Doses in Healthy Adult Subjects.

open access: yesAntimicrobial Agents and Chemotherapy, 2018
Meropenem-vaborbactam is a fixed combination of the novel β-lactamase inhibitor vaborbactam and the carbapenem antibiotic meropenem, developed for the treatment of serious infections caused by drug-resistant Gram-negative bacteria.
David C Griffith   +2 more
exaly   +2 more sources

Meropenem-Vaborbactam Tested Against Contemporary Gram-Negative Isolates Collected Worldwide During 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae.

open access: yesAntimicrobial Agents and Chemotherapy, 2017
We evaluated the activity of meropenem-vaborbactam against contemporary nonfastidious Gram-negative clinical isolates, including Enterobacteriaceae isolates with resistance phenotypes and carbapenemase genotypes.
Rodrigo E Mendes   +2 more
exaly   +2 more sources

Home - About - Disclaimer - Privacy